

INFORMATION DISCLOSURE CITATION		ATTY. DOCKET NO. 3665-167 APPLICANT	SERIAL NO. 10/560,774			
(Use several sheets if necessary)		SCHWEIGHOFFER et al.				
		FILING DATE December 14, 2005	GROUP 1617			
U.S. PATENT DOCUMENTS						
*EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
	5,847,010	12-1998	Hedgepeth			
	5,672,622	9-1997	Hedgepeth			
	5,977,305	11/1999	Wigler et al			
	5,851,784	12/1998	Owens et al			
	6,060,501	5/2000	Wachtel et al			
FOREIGN PATENT DOCUMENTS				TRANSLATION		
DOCUMENT	DATE	COUNTRY	CLASS	SUBCLASS	YES	NO
WO 00/40714	7/2000	WIPO				
WO 01/44449	6/2001	WIPO				
OTHER DOCUMENTS (including Author, Title, Date, Pertinent pages, etc.)						
Claims filed December 15, 2008 in Application No. 10/486,639						
Pitt et al. "Glutamate Excitotoxicity in a Model of Multiple Sclerosis". Nature. 2000; 6(1):67-70.						
Bever et al. The effects of 4-aminopyridine in multiple sclerosis patients: Results of a randomized, double-blind, placebocontrolled, crossover-trial. Neurology, 1994 Vol. 44:1054-1059.						
Bever et al. Treatment with oral 3,4 diaminopyridine improves leg strength in multiple sclerosis patients: Results of a randomized, double-blind, placebo-controlled, crossover-trial. Neurology, 1996 Vol. 47:1457-1462.						
Rasdn et al. Cloning and characterization of a cAMP-specific phosphodiesterase (TbPDE2B) from Trypanosoma brucei. PNAS, 2002 Vol. 99:4714-4719.						

Examination

/Sahar Javanmard/

Date Considered

07/24/2009

Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to application.

Form PTO-FB-A820 (Also PTO-1449)

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. -S.J.A.

1429383

INFORMATION DISCLOSURE CITATION		ATTY. DOCKET NO. 3665-167 APPLICANT	SERIAL NO. 10/560,774			
(Use several sheets if necessary)		SCHWEIGHOFFER et al. FILING DATE	GROUP			
		December 14, 2005	1617			
U.S. PATENT DOCUMENTS						
*EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
OTHER DOCUMENTS (including Author, Title, Date, Pertinent pages, etc.)						
Cherry et al, "Diazepam and rolipram differentially inhibit cyclic AMP-specific phosphodiesterases PDE4A1 and PDE4BE in the mouse", BIOCHEMICA ET BIOPHYSICA ACTA 1518, 2001 PP. 27-35.						
Mishra et al, "Calcium calmodulin and 3',5'-cyclic nucleotide phosphodiesterase activity in human muscular disorders", JOURNAL OF THE NEUROLOGICAL SCIENCES, 109, 1992, 215-218.						
Price et al, "Mémoire: Amyotrophic lateral sclerosis and Alzheimer's disease. Lessons from model systems", REV NEUROL (PARIS), 1997, 153: 8-9, pp. 484-495.						
Dinter, "Phosphodiesterase Type 4 Inhibitors", BioDrugs, Feb. 2000, 13 (2), pp. 87-94.						
Myers et al, "Pentoxifylline is not a promising treatment for multiple sclerosis in progression phase", AMERICAN ACADEMY OF NEUROLOGY, 1998, pp. 1483-1486.						
Branch, "A good antisense molecule is hard to find", TIBS, 23, February 1998, pp. 45-50.						
Crooke, "Basic Principles of Antisense Therapeutics", Chapter 1, pp. 1-50.						
Pihl-Carey, "Isis to Restructure as Crohn's Disease Drug Falls in Phase III", BIOWORLD TODAY, vol. 10, 239, December 1999, pp. 1-2.						
Jen et al, "Suppression of Gene Expression by Targeted Disruption of Messenger RNA: Available Options and Current Strategies", STEM CELLS 2000, 18:307-319.						
van Oosten, "A pilot study investigating the effects of orally administered pentoxifylline on selected immune variables in patients with multiple sclerosis", JOURNAL OF NEUROIMMUNOLOGY, 1996, 66, pp. 49-55.						
Friedman et al, "A Pilot Study of Pentoxifylline in Multiple Schlerosis", ARCHIVES OF NEUROLOGY, October 1996, Vol. 53, pp. 956-957.						
Brighina et al, "Recent Advances in the Therapy of Amyotrophic Lateral Sclerosis: Focus on Excitotoxicity", FUNCTIONAL NEUROLOGY (16), Suppl. 4, 2001, pp. 189-292.						
Ward et al., "Pentoxifylline-A Review of its Pharmacodynamic and Pharmacokinetic Properties, and its Therapeutic Efficacy", Drug Evaluation, Drugs 34: 50-97 (1987).						
Leigh et al., "Excitotoxicity in ALS", Nerol. 1996 47 (Supp 4), S221-7.						
Ludolph et al., "The role of excitotoxicity in ALS - what is the evidence?", J. of Neurol. 2000, 247 (Supp 1) 7-16.						
Rothstein, "Excitotoxicity and Neurodegeneration in Amyotrophic Lateral Sclerosis", Clin Neurosc 95-96 3(6) 348-59.						
Rothstein, "Excitotoxicity hypothesis", Neurol 1996 47 (Supp 4) S19-25.						
Examiner	/Sahar Javanmardi/		Date Considered	07/24/2009		

Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered.
Include copy of this form with next communication to application.

Form PTO-FB-A820 (Also PTO-1449)

INFORMATION DISCLOSURE CITATION		ATTY. DOCKET NO. 3665-167 APPLICANT	SERIAL NO. 10/560,774
(Use several sheets if necessary)		SCHWEIGHOFER et al. FILING DATE	GROUP
		December 14, 2005	1617
OTHER DOCUMENTS (including Author, Title, Date, Pertinent pages, etc.)			
Doble, "The pharmacology and mechanism of action of riluzole", AMERICAN ACADEMY OF NEUROLOGY, 1996, pp. S233-S241.			
Bar, "Motor neuron disease in vitro: the use of cultured motor neurons to study amyotrophic lateral sclerosis", EUROPEAN JOURNAL OF PHARMACOLOGY, 405, 2000, pp. 285-295.			
Sommer et al, "Therapeutic potential of phosphodiesterase type 4inhibition in chronic autoimmune demyelinating disease", JOURNAL OF NEUROIMMUNOLOGY, 79, 1997, pp. 54-61.			
Beghi et al, "A randomized controlled trial of recombinant interferon beta-1a in ALS", AMERICAN ACADEMY OF NEUROLOGY, 2000, pp. 469-473.			
Jahn et al, "Mechanism of block of nicotinic acetylcholine receptor channels by purified IgG from seropositive patients with myasthenia gravis, AMERICAN ACADEMY OF NEUROLOGY, 2000, p. 474.			
Asahara et al, "Glutamate enhances phosphorylation of neurofilaments in cerebellar granule cell culture", JOURNAL OF THE NEUROLOGICAL SCIENCES, 171, 1999, 84-87 (first page attached).			
Houslay, PROGRESS IN NUCLEIN ACID RESEARCH AND MOLECULAR BIOLOGY, Vol. 69, 1001, 249-315 (first page attached).			
Snider et al, "Signaling the Pathway to Regeneration", NEURON 2002, 35, 13-6 (first page attached).			
Santos et al, "Cyclic AMP increases the survival of ganglion cells in mixed retinal cell cultures in the absence of exogenous neurotrophic molecules, an effect that involves cholinergic activity", BRAZ J. MED BIOL RES, 2001m, 34, 1585-1593, pp. 1585-1593 (first page attached).			
Feldman et al, "Breathing: Rhythmicity, Plasticity, Chemosensitivity", ANNU REV NEUROSCI 2003, 26, pp. 239-266 (first page attached).			
Polman et al, "Clinical review: Drug treatment of multiple sclerosis", BMJ, Volume 321, 19-26 August 2000, pp. 490-494.			
Compston et al, "Multiple sclerosis", THE LANCET, Vol. 359, April 6, 2002, pp. 1221-31.			
Rowland et al, "Amyotrophic Lateral Sclerosis", N. ENGL. J. MED., Vol. 344, No. 22, May 31, 2001, pp. 1688-1700.			
Kempermann et al, "Functional significance of adult neurogenesis", Current Opinion in Neurobiology 2004, 14:186-191			
Examiner /Sahar Javamard/		Date Considered	07/24/2009

Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered.
Include copy of this form with next communication to application.